OTCPK:EVNN.F

Stock Analysis Report

Executive Summary

Eviana Health Corporation produces and sells cannabinoid products from natural hemp strains of cannabis sativa for medical, beauty and grooming, vitamins and supplements, fitness, food and beverage, and pet markets.


Snowflake Analysis

Imperfect balance sheet and overvalued.

Share Price & News

How has Eviana Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EVNN.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

EVNN.F

15.7%

US Chemicals

9.4%

US Market


1 Year Return

n/a

EVNN.F

-22.5%

US Chemicals

-6.8%

US Market

Return vs Industry: Insufficient data to determine how EVNN.F performed against the US Chemicals industry.

Return vs Market: Insufficient data to determine how EVNN.F performed against the US Market.


Shareholder returns

EVNN.FIndustryMarket
7 Day0%15.7%9.4%
30 Day0%-1.2%-3.9%
90 Dayn/a-19.6%-16.5%
1 Yearn/a-17.3%-22.5%-4.8%-6.8%
3 Yearn/a3.4%-16.4%23.4%15.2%
5 Yearn/a11.3%-13.2%41.3%25.7%

Price Volatility Vs. Market

How volatile is Eviana Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Eviana Health undervalued compared to its fair value and its price relative to the market?

0.33x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EVNN.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EVNN.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EVNN.F is unprofitable, so we can't compare its PE Ratio to the Chemicals industry average.

PE vs Market: EVNN.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EVNN.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EVNN.F is good value based on its PB Ratio (0.3x) compared to the US Chemicals industry average (1.5x).


Next Steps

Future Growth

How is Eviana Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.6%

Forecasted Materials industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eviana Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of EVNN.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Eviana Health's filings and announcements here.
  • Explore growth companies in the Materials industry.

Past Performance

How has Eviana Health performed over the past 5 years?

34.7%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: EVNN.F is currently unprofitable.

Growing Profit Margin: EVNN.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if EVNN.F's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare EVNN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EVNN.F is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-11.3%).


Return on Equity

High ROE: EVNN.F has a negative Return on Equity (-87.79%), as it is currently unprofitable.


Next Steps

Financial Health

How is Eviana Health's financial position?


Financial Position Analysis

Short Term Liabilities: EVNN.F's short term assets (CA$11.1M) exceed its short term liabilities (CA$2.3M).

Long Term Liabilities: EVNN.F's short term assets (CA$11.1M) exceed its long term liabilities (CA$8.0M).


Debt to Equity History and Analysis

Debt Level: EVNN.F's debt to equity ratio (170%) is considered high.

Reducing Debt: Insufficient data to determine if EVNN.F's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if EVNN.F has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if EVNN.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Eviana Health's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EVNN.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EVNN.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EVNN.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVNN.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EVNN.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average board tenure


CEO

Avram Adizes

2.67s

Tenure

CA$120,000

Compensation

Dr. Avram Adizes, Ph.D., P.E., serves as the Chief Technology Officer of Phoenix Capital Partners Inc. Dr. Adizes is responsible for Technology assessment and evaluation. Dr. Adizes serves as Chairman and  ...


CEO Compensation Analysis

Compensation vs Market: Avram's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD614.05K).

Compensation vs Earnings: Insufficient data to compare Avram's compensation with company performance.


Board Members

NamePositionTenureCompensationOwnership
Avram Adizes
Chairman of the Board & CEO2.67yrsCA$120.00k7.49% CA$83.4k
Wai Au
CFO & Director6.83yrsCA$60.00k0.92% CA$10.3k
Joel Sherlock
Member of Advisory Board1.75yrsno datano data
Ljiljana Vujotic
Director2.67yrsCA$100.00k6.28% CA$69.8k

2.7yrs

Average Tenure

Experienced Board: EVNN.F's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.9%.


Top Shareholders

Company Information

Eviana Health Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eviana Health Corporation
  • Ticker: EVNN.F
  • Exchange: OTCPK
  • Founded: 2011
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: CA$1.553m
  • Listing Market Cap: CA$1.113m
  • Shares outstanding: 23.90m
  • Website: https://eviana.ca

Location

  • Eviana Health Corporation
  • 5728 East Boulevard
  • Vancouver
  • British Columbia
  • V6M 4M4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EHCCNSX (Canadian National Stock Exchange)YesCommon SharesCACADSep 2017
EVNN.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 2017
1CPDB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2017

Biography

Eviana Health Corporation produces and sells cannabinoid products from natural hemp strains of cannabis sativa for medical, beauty and grooming, vitamins and supplements, fitness, food and beverage, and pet markets. It is also involved in the growing of industrial hemp and extraction of cannabidiol. The company was formerly known as C&C Cosmeceuticals Corp. and changed its name to Eviana Health Corporation in May 2017. Eviana Health Corporation was incorporated in 2011 and is headquartered in Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/10 01:17
End of Day Share Price2020/02/21 00:00
Earnings2019/03/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.